MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 596975 | Name: Octreotide pamoate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Octreotide pamoate is an antineoplastic.

Chemical Structure

Octreotide pamoate
Octreotide pamoate
CAS#135467-16-2 (pamoate)

Theoretical Analysis

MedKoo Cat#: 596975

Name: Octreotide pamoate

CAS#: 135467-16-2 (pamoate)

Chemical Formula: C72H82N10O16S2

Exact Mass: 0.0000

Molecular Weight: 1407.62

Elemental Analysis: C, 61.44; H, 5.87; N, 9.95; O, 18.19; S, 4.56

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
79517-01-4 (acetate) 83150-76-9 (free base) 1607842-55-6 (HCl) 135467-16-2 (pamoate)
Synonym
Octreotide pamoate; SMS pa; SMS 201-995 pa;
IUPAC/Chemical Name
(4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-19-((R,E)-2-amino-4-methylhepta-4,6-dienamido)-10-(4-aminobutyl)-16-benzyl-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide 4,4'-methylenebis(3-hydroxy-2-naphthoate)
InChi Key
KFWJVABDRRDUHY-RJVYUNNPSA-N
InChi Code
InChI=1S/C49H66N10O10S2.C23H16O6/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41;24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64);1-10,24-25H,11H2,(H,26,27)(H,28,29)/t28-,29-,34+,36+,37+,38+,39-,40+,41+,42+;/m1./s1
SMILES Code
[H]N[C@H](C(N[C@H]1CSSC[C@@H](C(N[C@@H]([C@H](O)C)CO)=O)NC([C@H]([C@H](O)C)NC([C@@H](NC([C@@H](NC([C@@H](NC1=O)CC2=CC=CC=C2)=O)CC3=CNC4=C3C=CC=C4)=O)CCCCN)=O)=O)=O)CC5=CC=CC=C5.OC(C6=CC7=C(C(CC8=C(C(C(O)=O)=CC9=C8C=CC=C9)O)=C6O)C=CC=C7)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,407.62 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zhao P, Sharir H, Kapur A, Cowan A, Geller EB, Adler MW, Seltzman HH, Reggio PH, Heynen-Genel S, Sauer M, Chung TD, Bai Y, Chen W, Caron MG, Barak LS, Abood ME. Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol Pharmacol. 2010 Oct;78(4):560-8. doi: 10.1124/mol.110.066746. Epub 2010 Jul 22. PubMed PMID: 20826425; PubMed Central PMCID: PMC2981393. 2: Helle SI, Mietlowski W, Guastalla JP, Szakolczai I, Bajetta E, Sommer H, Baltali E, Pinter T, Csepreghy M, Ottestad L, Boni C, Bryce C, Klijn JG, Lønning PE. Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy. Eur J Cancer. 2005 Mar;41(5):694-701. Epub 2005 Jan 21. PubMed PMID: 15763644. 3: Welin SV, Janson ET, Sundin A, Stridsberg M, Lavenius E, Granberg D, Skogseid B, Oberg KE, Eriksson BK. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol. 2004 Jul;151(1):107-12. PubMed PMID: 15248829. 4: Khanna C, Prehn J, Hayden D, Cassaday RD, Caylor J, Jacob S, Bose SM, Hong SH, Hewitt SM, Helman LJ. A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. Clin Cancer Res. 2002 Jul;8(7):2406-12. PubMed PMID: 12114446. 5: Bajetta E, Procopio G, Ferrari L, Martinetti A, Zilembo N, Catena L, Alú M, Della TS, Alberti D, Buzzoni R. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Cancer. 2002 Jan 15;94(2):299-304. PubMed PMID: 11900215. 6: Helle SI, Geisler J, Poulsen JP, Hestdal K, Meadows K, Collins W, Tveit KM, Holly JM, Lønning PE. Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study. Br J Cancer. 1998 Jul;78(1):14-20. PubMed PMID: 9662244; PubMed Central PMCID: PMC2062954. 7: Goni MH, Markussis V, Tolis G. Octreotide effect on ovarian morphology in insulin-resistant PCOS patients following six-month decapeptyl treatment. Am J Reprod Immunol. 1994 Mar-Apr;31(2-3):104-11. PubMed PMID: 8049019. 8: Redding TW, Schally AV. Use of analogs of LH-RH and somatostatin for the treatment of hormone dependent cancers. Prog Clin Biol Res. 1988;262:217-40. PubMed PMID: 2897695. 9: Zalatnai A, Paz-Bouza JI, Redding TW, Schally AV. Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D-Trp-6-LH-RH. Prostate. 1988;12(1):85-98. PubMed PMID: 2894651. 10: Schally AV, Redding TW. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Proc Natl Acad Sci U S A. 1987 Oct;84(20):7275-9. PubMed PMID: 2890164; PubMed Central PMCID: PMC299275.

View History

Zeniplatin

Zeniplatin

KSL-128114

KSL-128114

GW-282974X

GW-282974X

IT-15 HCl

IT-15 HCl

Buthalital

Buthalital

Zicronapine succinate

Zicronapine succinate